ArticleAmerican journal of translational research2025
Exploration of the mechanism of Tongmai Jiangzhuo Decoction in treating atherosclerosis based on network pharmacology and experimental validation.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAtherosclerosis (AS) is a dyslipidemia-driven immunoinflammatory disease. While Tongmai Jiangzhuo Decoction (TMJZ) clinically improves cardiovascular outcomes through lipid-lowering effects, its molecular mechanisms against AS remain unelucidated. This study aimed to systematically investigate the anti-atherogenic mechanisms of TMJZ.
methodsMain active components of TMJZ and their targets were identified using Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and Bioinformatics Analysis Tool for Molecular mechANism of TCM (BATMAN-TCM). Potential therapeutic targets were sourced from Online Mendelian Inheritance in Man (OMIM) and GeneCards. Protein-protein interactions (PPI) network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted using Cytoscape. Molecular docking was performed with AutoDockTools, AutoDock Vina, and PyMOL. Apolipoprotein E (ApoE)-deficient mice were used to validate the targets.
resultsA total of 395 predicted intersection target genes between TMJZ targets and atherogenic-related targets were identified. Key anti-atherosclerosis targets of TMJZ included Peroxisome Proliferator-Activated Receptor Gamma (PPARγ), Cluster of Differentiation 36 (CD36, fatty acid translocase), Interleukin 6 (IL6), Insulin (INS), AKT Serine/Threonine Kinase 1 (AKT1), Tumor Necrosis Factor (TNF), Tumor Protein p53 (TP53), Interleukin 1 Beta (IL1B), Catenin Beta 1 (CTNNB1), and Apolipoprotein E (APOE). Among these, PPARγ/CD36 signaling emerged as a pivotal pathway. In vivo studies demonstrated that TMJZ improved blood lipids, reduced plaque area and lipid deposition, upregulated PPARγ expression, and downregulated CD36 expression in aortic tissues. Additionally, TMJZ upregulated Liver X Receptor Alpha (LXRα) and ATP Binding Cassette Subfamily A Member 1 (ABCA1), promoting reverse cholesterol transport.
conclusionsTMJZ alleviates atherosclerosis by inhibiting lipid uptake via the PPARγ/CD36 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.